|
Synonyms: Effi-7
Compound class:
Antibody
Comment: OSE-127 is a humanised monolonal antibody targeting the α subunit of the IL-7 receptor (IL-7RA, or CD127). It is in preclinical development in autoimmune diseases, transplant rejection and immuno-oncology. It is likely one of the candidates claimed in patent WO2015189302 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Based on our assumption that OSE-127 is claimed in WO2015189302 [2], we have chosen one of the humanised antibodies disclosed therein (N13B2-h3) to calculate an approximate binding EC50 value, using an average molecular weight of 150kDa for the antibody (data provided in the patent is in ng/ml). OSE-127 acts as a functional antagonist of the IL-7/IL-7Rα interaction, blocking heterodimer formation of the IL-7Rα/IL-2Rγ signalling competent complex, preventing internalisation of the bound receptor and blocking downstream activation of T cells and production of IFNγ. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
